UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000009715
Receipt No. R000011318
Scientific Title A randomized controlled trial comparing laparoscopic surgery with open surgery in palliative resection of primary tumor in incurable Stage IV colorectal cancer (JCOG1107)
Date of disclosure of the study information 2013/01/07
Last modified on 2018/02/14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A randomized controlled trial comparing laparoscopic surgery with open surgery in palliative resection of primary tumor in incurable Stage IV colorectal cancer (JCOG1107)
Acronym Encore Trial: Trial of <en>doscopic palliative <co>lorectal <re>section for
symptomatic unresectable colorectal cancer (JCOG1107)
Scientific Title A randomized controlled trial comparing laparoscopic surgery with open surgery in palliative resection of primary tumor in incurable Stage IV colorectal cancer (JCOG1107)
Scientific Title:Acronym Encore Trial: Trial of <en>doscopic palliative <co>lorectal <re>section for
symptomatic unresectable colorectal cancer (JCOG1107)
Region
Japan

Condition
Condition Unresectable Stage IV colorectal cancer and a synchronous symptomatic primary tumor
Classification by specialty
Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To confirm the non-inferiority of laparoscopic primary tumor resection in overall survival compared to open resection for symptomatic unresectable colorectal cancer.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase Phase III

Assessment
Primary outcomes Progression-free survival
Key secondary outcomes Overall survival, proportion of conversion from laparoscopic surgery to open surgery, proportion of patients who fulfill the criteria of starting chemotherapy by 6 weeks after operation, intraoperative and postoperative complication, adverse events during chemotherapy, serious adverse events

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification NO
Dynamic allocation YES
Institution consideration Institution is considered as adjustment factor in dynamic allocation.
Blocking NO
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine Maneuver
Interventions/Control_1 A: Open primary tumor resection followed by chemotherapy (mFOLFOX6 or CapeOX plus bevacizumab; mFOLFOX6: bevacizumab 5 mg/kg IV on day 1, l-leucovorin 200 mg/m2 and oxaliplatin 85 mg/m2 as a 2-hour IV on day 1, 5-FU 400 mg/m2 IV bolus on day 1 followed by 2,400 mg/m2 IV over 46 hours, repeated every 2 weeks; CapeOX: bevacizumab 7.5 mg/kg IV and oxaliplatin 130 mg/m2 as a 2-hour IV on day 1 and Capecitabine 1000 mg/m2 per day orally from day 1 to day 14, repeated every 2 weeks)
Interventions/Control_2 B: Laparoscopic primary tumor resection followed by the same chemotherapy as arm A (mFOLFOX6 or CapeOX plus bevacizumab)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
74 years-old >=
Gender Male and Female
Key inclusion criteria 1. Pathologically proven adenocarcinoma or adenosquamous carcinoma
2. Primary tumor located at Cecum, Ascending, Transverse, Descending, Sigmoid, Rectosigmoid
3. Primary tumor with bowel stenosis (no obstruction) and/or bleeding (Hb<9.0 or blood transfusion within 4 weeks). If emergency operation is needed, the patient is ineligible.
4. Having at least one to up to three unresectable factors among the following four factors:
(1) Hepatic metastases with the predicted remnant functional parenchyma of less than 30%
(2) Pulmonary metastases meeting one of the followings:
i) Invasion suspected to the mediastinum, heart, large vessels, trachea, esophagus, vertebral body, or tracheal bifurcation
ii) Predicted postoperative lung function (%FEV1.0) of less than 40%
iii) Requiring total pneumonectomy for removal of all metastatic tumors
iv) Malignant pleural effusion or pleural dissemination
(3) Distant lymph node (LN) metastases with 10 mm or greater short axis which fulfill one of the followings by CT scan:
i) LN enlargement located above the lower edge of renal vein
ii) LN enlargement along the common hepatic artery or the hepatoduodenal ligament with hepatic metastases
iii) Mediastinal or hilar LN enlargement with pulmonary metastases
(4) Peritoneal metastases meeting one of the followings:
i) Multiple irregularities or strictures of the intestinal walls confirmed by imaging
ii) Peritoneal tumor above the transverse colon
5. No apparent invasion to adjacent organs
6. No ascites above the pelvic cavity
7. Neither bone metastases nor brain metastases
8. No history of abdominal surgery
9. PS of 0, 1, or 2
10. Aged 20 to 74 years old
11. No prior treatment of chemotherapy or radiation therapy against any other malignancies, including colorectal cancer
12. Adequate organ functions defined as below
(1) Neutrophil count>=1,500/mm3
(2) Platelet count>=100000/mm3
(3) AST=<100IU/L
(4) ALT=<100IU/L
Key exclusion criteria 1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal carcinoma
2) Infectious disease to be treated
3) HBs antigen positive
4) Body temparature >= 38c
5) Women during pregnancy, possible pregnancy or breast-feeding
6) Severe mental disease
7) Currently treated with systemic steroids
8) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema
9) Uncontrollable diabetes mellitus or routine administration of insulin
10) Uncontrolled hypertension, defined as systolic >= 150 and/or diastolic >= 100 mmHg
11) New York Heart Association class III /IV cardiac disease or congestive heart failure that would take medication in order to prevent lethal ventricular arrhythmias
12) Gastrointestinal fistula, perforation, or abscess within 6 months
13) Unstable angina pectoris, previous myocardial infarction, or arterial thrombotic event within 6 months
14) Abdominal aortic aneurysm (>= 5cm), thoracic aortic aneurysm (>= 6cm), or aortic dissection
15) Congenital hemorrhagic diathesis, coagulation disorder, or significant episodes of acute bleeding of grade 3 or more according to CTCAE ver.4.0 within the past 28 days
16) Episodes of hemoptysis within 28 days
Target sample size 194

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Seigo Kitano
Organization Oita University Faculty of Medicine
Division name First Surgery
Zip code
Address 1-1, Idaigaoka, Hazama-cho, Yufu-city, 879-5593 Japan
TEL 097-586-5843
Email colonrct@oita-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Tomonori Akagi, Masafumi Inomata
Organization JCOG1107 Coordinating Office
Division name First Surgery, Oita University Faculty of Medicine
Zip code
Address 1-1, Idaigaoka, Hazama-cho, Yufu-city, 879-5593 Japan
TEL 097-586-5843
Homepage URL http://www.jcog.jp/
Email JCOG_sir@ml.jcog.jp

Sponsor
Institute Japan Clinical Oncology Group (JCOG)
Institute
Department

Funding Source
Organization Ministry of Health, Labour and Welfare
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 札幌厚生病院(北海道)
岩手医科大学(岩手県)
宮城県立がんセンター(宮城県)
山形県立中央病院(山形県)
栃木県立がんセンター(栃木県)
防衛医科大学校(埼玉県)
埼玉県立がんセンター(埼玉県)
自治医科大学附属さいたま医療センター(埼玉県)
埼玉医科大学国際医療センター(埼玉県)
国立がん研究センター東病院(千葉県)
千葉県がんセンター(千葉県)
順天堂大学医学部附属浦安病院(千葉県)
国立がん研究センター中央病院(東京都)
杏林大学医学部(東京都)
がん・感染症センター都立駒込病院(東京都)
慶應義塾大学病院(東京都)
東京医科歯科大学(東京都)
東邦大学医療センター大橋病院(東京都)
神奈川県立病院機構神奈川県立がんセンター(神奈川県)
北里大学医学部(神奈川県)
昭和大学横浜市北部病院(神奈川県)
横浜市立大学附属市民総合医療センター(神奈川県)
済生会横浜市南部病院(神奈川県)
平塚市民病院(神奈川県)
新潟県立がんセンター新潟病院(新潟県)
新潟県厚生連長岡中央綜合病院(新潟県)
石川県立中央病院(石川県)
長野市民病院(長野県)
岐阜大学医学部(岐阜県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院(愛知県)
藤田保健衛生大学(愛知県)
国立病院機構京都医療センター(京都府)
大阪大学医学部(大阪府)
大阪国際がんセンター(大阪府)
国立病院機構大阪医療センター(大阪府)
大阪急性期・総合医療センター(大阪府)
大阪市立総合医療センター(大阪府)
大阪医科大学(大阪府)
箕面市立病院(大阪府)
市立吹田市民病院(大阪府)
関西労災病院(兵庫県)
兵庫医科大学(兵庫県)
岡山済生会総合病院(岡山県)
広島市立広島市民病院(広島県)
県立広島病院(広島県)
広島市立安佐市民病院(広島県)
福山市民病院(広島県)
国立病院機構四国がんセンター(愛媛県)
高知医療センター(高知県)
久留米大学医学部(福岡県)
熊本大学医学部(熊本県)
大分大学医学部附属病院(大分県)

Other administrative information
Date of disclosure of the study information
2013 Year 01 Month 07 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2012 Year 11 Month 09 Day
Date of IRB
Anticipated trial start date
2013 Year 01 Month 07 Day
Last follow-up date
2024 Year 07 Month 07 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2013 Year 01 Month 07 Day
Last modified on
2018 Year 02 Month 14 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011318

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.